IPO’s Draft Pharma Patent Guidelines Face Legal Criticism
The IPO’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026, have drawn strong criticism for misquoting statutory provisions and introducing legally unsound interpretations. Stakeholders urge comprehensive revision before finalization.